Intermountain Precision Genomics continues to expand cancer testing through advancements to TheraMap, a test for advanced-stage cancer patients. Using state-of-the-art genomic technology, TheraMap analyzes and interprets gene mutations in a patient’s tumor DNA—with the ability to detect mutation types across more than 500 genes relevant to cancer treatment.
“Our unique process analyzes the genetic makeup of a patient’s cancer and employs a team of skilled molecular tumor specialists to review each solid tumor test and determine how to most effectively treat that case,” said Lincoln Nadauld, MD, PhD, oncologist and chief of precision health and genomics at Intermountain Healthcare. “Our approach gives oncologists the information to prepare a targeted treatment plan for each patient.”
Compared to traditional diagnostic tests and treatment, TheraMap’s methods provide significantly better results for patients, at lower overall healthcare costs—something patient Jeffery Layne can attest to.
In January 2018, Layne was diagnosed with stage-four kidney cancer that had spread to other parts of his body and was given six months to two years to live. Layne’s oncologist, Derrick Haslem, MD, associate medical director for the Intermountain Healthcare Oncology Clinical Program, recommended TheraMap.
Using TheraMap’s results, Dr. Haslem discovered Layne would be a good candidate for immunotherapy treatment, a personalized infusion that boosts the body’s own immune system to fight cancer.
Layne quickly responded to the treatment with masses under his arms shrinking almost immediately. After two months of immunotherapy, the masses disappeared and tumors on his lungs were significantly smaller. Two years later, Layne continues to improve while painting and spending time with his grandkids. Watch Layne’s story in this video.
“Intermountain Precision Genomics is pleased with the advances in TheraMap that will continue to help our advanced-cancer patients see a longer, improved quality of life,” said Dr. Nadauld.